Alicia Morgan, MD

Articles by Alicia Morgan, MD

Alicia Morgans, MD, MPH, member, faculty of medicine, Harvard Medical School, medical director, Survivorship Program, Dana-Farber Cancer Institute

Dr. Morgans on the Current Treatment Landscape For mHSPC

January 18th 2023

Alicia Morgans, MD, MPH, discusses current androgen deprivation therapy combinations and the investigation of radiopharmaceutical combinations for metastatic hormone-sensitive prostate cancer.

Dr. Morgan on Combinations With PARP Inhibitors in Prostate Cancer

ByAlicia Morgan, MD

February 7th 2018

Alicia Morgan, MD, Mather Hospital, discusses combinations with PARP inhibitors in prostate cancer.

Dr. Morgan Discusses the Impact of PARP Inhibitors in Prostate Cancer

ByAlicia Morgan, MD

February 1st 2018

Alicia Morgan, MD, Mather Hospital, discusses the impact of PARP inhibitors in prostate cancer.

Dr. Morgan on Enrolling Patients With Prostate Cancer onto Clinical Trials

ByAlicia Morgan, MD

January 20th 2018

Alicia Morgan, MD, Mather Hospital, discusses enrolling patients with prostate cancer onto clinical trials investigating PARP inhibitors.

Dr. Morgan on the Role of PARP Inhibitors in Prostate Cancer

ByAlicia Morgan, MD

January 17th 2018

Alicia Morgan, MD, Mather Hospital, discusses the role of PARP inhibitors for patients with prostate cancer.

Dr. Morgan on Olaparib for Metastatic Castration-Resistant Prostate Cancer

ByAlicia Morgan, MD

December 21st 2017

Alicia Morgan, MD, Mather Hospital, discusses the role of olaparib (Lynparza) for patients with metastatic castration-resistant prostate cancer (mCRPC).